Idexx Laboratories (IDXX) EPS (Weighted Average and Diluted) (2009 - 2026)

Idexx Laboratories' EPS (Weighted Average and Diluted) history runs 18 years deep, the most recent figure standing at $3.47 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 17.23% year-over-year to $3.47; the TTM figure through Mar 2026 stood at $13.59 (up 25.6% YoY), while the FY2025 annual figure was $13.08, up 22.59% from the prior year.
• EPS (Weighted Average and Diluted) was $3.47 for Q1 2026 at Idexx Laboratories, up from $3.09 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.63 in Q2 2025 to a low of $1.56 in Q2 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged $2.67 across 5 years, with a median of $2.62 in 2024.
• The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) tumbled 33.33% in 2022, then jumped 71.15% in 2023.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.06 in 2022, then increased by 12.14% to $2.31 in 2023, then climbed by 13.42% to $2.62 in 2024, then grew by 17.94% to $3.09 in 2025, then increased by 12.3% to $3.47 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $3.47 (Q1 2026), $3.09 (Q4 2025), and $3.4 (Q3 2025), per Business Quant data.